Association of miR-122 and miR-21 with the severity of HDV infection
Keywords:
HDV infection, miR-122, miR-21, liver cirrhosisAbstract
Background and aim: Hepatitis D is the most severe manifestation of chronic viral hepatitis, characterized by significant clinical ramifications. These repercussions encompass an elevated susceptibility to hepatic decompensation and the development of hepatocellular carcinoma (HCC), ultimately culminating in fatal outcomes. The role of miRs in the pathogenesis of this disease remains largely unexplored. Methods: The study enrolled 102 treatment naïve chronic hepatitis D patients. 31 patients had chronic hepatitis D and 71 patients liver cirrhosis of HDV aetiology. The EIA confirmed HDV infection with the following quantitative PCR. Results: Compared to LC patients, those with CHD showed significantly higher levels of miR-122 and lower levels of miR-21. miR-122 expression inversely correlated with the severity of liver cirrhosis, showing lower numbers in the group with LC Class A compared to the LC Class B. Meanwhile, the group of patients without liver cirrhosis had the highest values. miR-21 was also higher in the LC Class A group compared to LC class B and patients without liver cirrhosis. Conclusions: miR-122 and miR-21 could serve as an effective predictor for further decompensation of liver cirrhosis and exacerbation of the HDV infection process. This assumption requires further study in a larger sample.
References
Jelen M, Glavač D. Importance of MicroRNAs in Hepatitis B and C Diagnostics and Treatment. In: Naglaaa Allam, editor. Advances in Treatment of Hepatitis C and B. United Kingdom: Intechopen; 2017. 408 p. doi: 10.5772/66498.
Megahed F, Tabll A, Atta S, et al. MicroRNAs: Small Molecules with Significant Functions, Particularly in the Context of Viral Hepatitis B and C Infection. Medicina (Kaunas). 2023; Jan; 59(1):173. doi: 10.3390/medicina59010173.
Ostrycharz E, Hukowska-Szematowicz B. Micro-Players of Great Significance-Host microRNA Signature in Viral Infections in Humans and Animals. Int J Mol Sci. 2022; Sep 11;23(18):10536. doi: 10.3390/ijms231810536.
Louten J, Beach M, Palermino K, Weeks M, Holenstein G. MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic Considerations. Biomark Insights. 2015;10 (Suppl 4):25-52. doi: 10.4137/BMI.S29512.
Landgraf P, Rusu M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007;129 (7):1401-1414. doi: 10.1016/j.cell.2007.04.040.
Gamazon ER, Innocenti F, Wei R, et al. A genome-wide integrative study of microRNAs in human liver. BMC genomics. 2013;14:395. doi: 10.1186/1471-2164-14-395.
Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A. miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol. 2008; Apr;48(4):648-656. doi: 10.1016/j.jhep.2008.01.019.
Farci P, Niro GA, Zamboni F, Diaz G. Hepatitis D Virus and Hepatocellular Carcinoma. Viruses. 2021; May 4;13(5):830. doi: 10.3390/v13050830.
Niro GA, Ferro A, Cicerchia F, Brascugli I, Durazzo M. Hepatitis delta virus: From infection to new therapeutic strategies. World J Gastroenterol. 2021; Jun 28;27(24):3530-3542. doi: 10.3748/wjg.v27.i24.3530.
Khodjaeva M, Ibadullaeva N, Khikmatullaeva A, et al. The medical impact of hepatitis D virus infection in Uzbekistan. Liver Int. 2019; Nov;39(11):2077-2081. doi: 10.1111/liv.14243.
Adams BD, Kasinski AL, Slack FJ. Aberrant regulation and function of microRNAs in cancer. Curr Biol. 2014; Aug 18;24(16):R762-76. doi: 10.1016/j.cub.2014.06.043.
Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008; Dec 18;456(7224):980-984. doi: 10.1038/nature07511.
Rowe MM, Kaestner KH. The Role of Non-Coding RNAs in Liver Disease, Injury, and Regeneration. Cells. 2023; Jan 18;12(3):359. doi: 10.3390/cells12030359.
Nguyen HT, Kacimi SEO, Nguyen TL, et al. MiR-21 in the Cancers of the Digestive System and Its Potential Role as a Diagnostic, Predictive, and Therapeutic Biomarker. Biology 2021; 10(5), 417. doi:10.3390/biology10050417.
Sokhanvar Z, Elikaei A, Sharifi Z. Evaluation of miR-222 Expression in HBV Infected Patients in Comparison with HDV and HBV Co-infected Patients. Avicenna J Med Biotechnol. 2021; Oct-Dec; 13(4): 223–225. PMID: 34900149.
Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A. miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol. 2008; Apr;48(4):648-656. doi: 10.1016/j.jhep.2008.01.019.
Loyer X, Paradis V, Hénique C, et al. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression. Gut. 2016; Nov;65(11):1882-1894. doi: 10.1136/gutjnl-2014-308883.
Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. miR-122--a key factor and therapeutic target in liver disease. J Hepatol. 2015; Feb;62(2):448-457. doi: 10.1016/j.jhep.2014.10.004.
Qi, P, Cheng S, Wang H, Li N, Chen Y, Gao C. Serum MicroRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One. 2011;6(12):e28486. doi: 10.1371/journal.pone.0028486.
Mahmoudian-Sani MR, Asgharzade S, Alghasi A, Saeedi-Boroujeni A, Sadati SJA, Moradi MT. MicroRNA-122 in patients with hepatitis B and hepatitis B virus-associated hepatocellular carcinoma. J Gastrointest Oncol. 2019; Aug;10(4):789-796. doi: 10.21037/jgo.2019.02.14.
Wang S, Qiu L, Yan X, et al. Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1) -modulated P53 activity. Hepatology. 2012;55 (3):730-741. doi: 10.3389/fonc.2023.1204715.
Laleh RTA., Sharifi, Z, Pourfathollah AA. Correlation of serum microRNA-122 level with the levels of Alanine aminotransferase and HBV-DNA in Chronic HBV-infected patients. Med J Islam Repub Iran. 2021; Oct 19:35:137. doi: 10.47176/mjiri.35.137.
Arataki K, Hayes CN, Akamatsu S, Akiyama R. Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B. J Med Virol. 2013; May;85(5):789-98. doi: 10.1002/jmv.23540.
Xu J, Wu C, Che X, et al. Circulating microRNAs, Mir-21, Mir-122, and mir-223, in patients with hepatocellular carcinoma or chronic hepatitis. Molecular Carcinogenesis. 2010; December. doi:10.1002/mc.20712.
Kim WR, Benson JT, Therneau TM, Burritt MF, Melton LJ. Serum aminotransferase activity and risk of mortality in a U.S. community population. Hepatology. 2008;47. doi: 10.1002/hep.22090.
Zhang Y, Jia Y, Zheng R, et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem. 2010; Dec;56(12):1830-8. doi: 10.1373/clinchem.2010.147850.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Nargiz Ibadullaeva, Elizaveta Joldasova, Aziza Khikmatullaeva, Muazzam Abdukadirova, Malika Khodjaeva, Marina Bobkova, Erkin Musabaev
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
